ALKERMES | ALKS - Interest Expense On Debt


ALKERMES reported $25.92M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 25.92M 5.03M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 247M 7M Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Otsuka Holdings JPY 2.21B 866M Dec/2025
Ovoca Bio EUR 7K 6K Jun/2022
Pfizer USD 667M 4M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025